Trial
NCT03786094
Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Spexis AG
Collaborators
—
Condition
Metastatic Breast Cancer
Intervention
Eribulin
Why stopped
The study was halted early due to failure to meet the primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-01